All In MedTech

FDA Clearance Tracker · P160046-S019

VENTANA PD-L1 (SP263) CDx Assay

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 23, 2024

Approved

Time to decision

323 days

Received Dec 5, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P160046-S019
Device name
VENTANA PD-L1 (SP263) CDx Assay
Applicant location
Tucson, AZ
Received
Dec 5, 2023
Decided
Oct 23, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P160046

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval for the migration of the VENTANA PD-L1 (SP263) Assay from BenchMark ULTRA to BenchMark ULTRA PLUS instrument

Source documents

Other decisions for Ventana Medical Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.